Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
07 sept. 2022 07h00 HE
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
11 août 2022 08h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease
19 oct. 2020 08h00 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors
09 sept. 2020 08h00 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
08 juin 2020 08h15 HE
|
Cognition Therapeutics, Inc.
New York, June 08, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting
15 oct. 2019 08h03 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
27 nov. 2018 08h03 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
02 oct. 2018 08h02 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other ...
Nobilis Therapeutics Receives a Notice of Allowance for a Patent Covering Treatment of Psychiatric Disorders With Noble Gases
12 juin 2017 18h57 HE
|
Nobilis Therapeutics, Inc.
PORTLAND, Ore., June 12, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of...